首页> 外文OA文献 >176: Phase I/II Trial of Bortezomib Maintenance following Autologous Peripheral Blood Progenitor Cell Transplantation as Treatment for Intermediate- and Advanced-Stage Multiple Myeloma

【2h】

176: Phase I/II Trial of Bortezomib Maintenance following Autologous Peripheral Blood Progenitor Cell Transplantation as Treatment for Intermediate- and Advanced-Stage Multiple Myeloma

机译：176：自体外周血祖细胞移植作为中晚期多发性骨髓瘤的治疗后，硼替佐米维持的I / II期试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Schiller G.J.; Liao M.; Sohn J.P.; Malone R.; Bartoni K.; Habtemariam B.; Paquette R.; De Vos S.; Territo M.;
展开▼
作者单位

展开▼
年度 2008
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response. [J] . Robert M Rifkin, Andrew Greenspan, John F Schwerkoske, Investigational new drugs. . 2012,第2期

机译：硼替佐米的II期开放标签试验在患有多发性骨髓瘤的患者中进行，这些患者已经进行了自体外周血干细胞移植，但未能获得完全的应答。
2. A Phase I/II Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study [J] . Park Sung-Soo, Kim Kihyun, Kim Seok-Jin, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2019,第7期

机译：None
3. A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma [J] . Biran Noa, Rowley Scott D., Vesole David H., Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2016,第12期

机译：I / II期研究增加剂量的硼替佐米联合大剂量美法仑作为挽救自体外周血干细胞移植治疗多发性骨髓瘤的条件疗法
4. TESTING OF CRYOPRESERVED CONCENTRATES AT INFUSION LEADS TO STANDARDIZATION OF ENGRAFTMENT IN AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION [C] . MERICKA P., STRAKOVA H., LANSKA M., Congres International du Froid de I'IIF . 2011

机译：在输注时对冷冻保存浓缩物的测试导致自体外周血祖细胞移植中的植入标准化
5. A *longitudinal quality of life analysis of patients during the acute phase of autologous peripheral blood stem cell transplant. [D] . Quiett, Kimberly. 2006

机译：自体外周血干细胞移植急性期患者的纵向生活质量分析。
6. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd UK-MRA Myeloma XII trial): study protocol for a Phase III randomised controlled trial [O] . Alina Striha, A. John Ashcroft, Anna Hockaday, 2018

机译：ixazomib在复发性多发性骨髓瘤患者中作为挽救性自体干细胞移植（ASCT）的增强条件疗法以及ASCT后巩固和维持策略的作用（ACCoRd UK-MRA Myeloma XII试验）： III期随机对照试验
7. 153: Phase I/II trial of bortezomib maintenance following autologous peripheral blood progenitor cell transplantation as treatment for intermediate- and advanced-stage multiple myeloma [O] . Schiller G.J., Sohn J.P., Malone P., 2007

机译：153：自体外周血祖细胞移植治疗中晚期多发性骨髓瘤后硼替佐米维持的I / II期试验

176: Phase I/II Trial of Bortezomib Maintenance following Autologous Peripheral Blood Progenitor Cell Transplantation as Treatment for Intermediate- and Advanced-Stage Multiple Myeloma

著录项

引文网络

相似文献

相关主题

期刊订阅